Invega(paliperidone)
Byannli, Invega, Trevicta, Xeplion (paliperidone) is a small molecule pharmaceutical. Paliperidone was first approved as Invega on 2006-12-19. It is used to treat bipolar disorder, depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat psychotic disorders and schizophrenia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Invega, Invega hafyera, Invega sustenna, Invega trinza (generic drugs available since 2015-08-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Paliperidone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVEGA | Johnson & Johnson | N-021999 RX | 2006-12-19 | 4 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| invega sustenna | New Drug Application | 2022-08-15 |
| paliperidone | NDA authorized generic | 2023-01-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| depressive disorder | EFO_1002014 | D003866 | F32.A |
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PALIPERIDONE PALMITATE, INVEGA HAFYERA, JANSSEN PHARMS | |||
| 2024-08-30 | NS | ||
PALIPERIDONE PALMITATE, INVEGA TRINZA, JANSSEN PHARMS | |||
| 2024-08-30 | NS | ||
HCPCS
Code | Description |
|---|---|
| J2426 | Injection, paliperidone palmitate extended release, 1 mg |
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 35 | 7 | 44 | 40 | 11 | 135 |
| Psychotic disorders | D011618 | F20.81 | 8 | 1 | 5 | 9 | — | 23 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 3 | — | 4 | 1 | 3 | 11 |
| Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | 1 | 1 | 2 | ||
| Hyperprolactinemia | D006966 | E22.1 | — | — | — | 1 | — | 1 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | — | 1 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | 1 | — | 1 |
| Acute disease | D000208 | — | — | — | 1 | — | 1 | ||
| Psychomotor agitation | D011595 | — | — | — | 1 | — | 1 | ||
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | 2 | — | — | 3 |
| Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Depression | D003863 | F33.9 | — | — | 1 | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Drug therapy | D004358 | — | 1 | 1 | — | — | 1 | ||
| Tic disorders | D013981 | F95 | — | 1 | 1 | — | — | 1 | |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | 1 | — | — | 1 |
| Mania | D000087122 | F30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizotypal personality disorder | D012569 | F21 | 1 | — | — | — | — | 1 | |
| Immunoassay | D007118 | 1 | — | — | — | — | 1 | ||
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PALIPERIDONE |
| INN | paliperidone |
| Description | 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one is a member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2. It is a member of 1,2-benzoxazoles, a heteroarylpiperidine, an organofluorine compound, a pyridopyrimidine and a secondary alcohol. |
| Classification | Small molecule |
| Drug class | antipsychotics (risperidone type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O |
Identifiers
| PDB | — |
| CAS-ID | 1020719-55-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1621 |
| ChEBI ID | 83804 |
| PubChem CID | 115237 |
| DrugBank | DB01267 |
| UNII ID | 838F01T721 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Invega - Alkermes
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Invega - Johnson & Johnson
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,872 documents
View more details
Safety
Black-box Warning
Black-box warning for: Invega sustenna, Paliperidone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
57,491 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more